CASE HUB (appeals lodged at the General Court in Cases T- 680/14 (Lupin), T-682/14 (Mylan), T-679/14 (Teva), T-6824/14 (Krka), T-701/14 (Niche Generics) and T-701/14 (Unichem)) ARCHIVED–this archived case hub reflects the position at the date of the decision of 9 July 2014; it is no longer maintained. See further, timeline, commentary and related cases. Case facts Outline European Commission Articles 101 and 102 TFEU investigation into Servier and others (Perindopril) (case number COMP/39.612). The Commission issued fines totalling €427.7m on 09/07/2014. Latest developments On 9 July 2014, the Commission fined Servier and the five generic companies a combined €427.7m.Servier was fined €330.9972m, in relation to both the breaches of Articles 101 and 102 TFEU.Of the generic producers:• Niche and Unichem were fined €13,968,773 (jointly and severally liable), • Matrix was fined €17,161,140 (of which its new owner Mylan Inc. is jointly and severally liable for €8,045,914),• the Teva companies were fined €15,569,395 (jointly and severally liable),• Krka was fined €10m, and• Lupin was fined €40m.The Commission opened its investigation in July 2009 and sent a Statement of Objections